| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1916114 | Journal of the Neurological Sciences | 2007 | 4 Pages |
Abstract
Preliminary data suggest potential benefit of 5-HT receptor agonists in the treatment of ataxias. We studied the effects of buspirone in a cohort of twenty patients with spinocerebellar ataxia (SCA). Twenty patients were treated in this double-blind, placebo controlled, cross-over trial with either buspirone HCl 30 mg twice daily or placebo for 3 months. Buspirone was not shown to be superior to placebo in the treatment of patients with SCA.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Mitra Assadi, Joseph V. Campellone, Christopher G. Janson, J. Jon Veloski, Robert J. Schwartzman, Paola Leone,